FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3. FS118 is designed to provide unique pharmacology, that drives PD-L1 dependent LAG-3 shedding and receptor down-regulation, via bispecific activity, and potentially offering a more durable response in patients. Internal data and external validation of LAG-3 justifies its reputation as the next significant checkpoint inhibitor target in IO.
In the Phase 1 clinical trial, FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg. The Phase 2 proof-of-concept in checkpoint inhibitor relapsed head and neck cancer patients is ongoing.
In addition to the proof-of-concept trial in checkpoint relapsed head and neck patients, a CPI-naïve Phase 2 study in patients with non-small cell lung cancer (NSCLC) and diffuse large B cell lymphoma (DLBCL) is underway. FS118 has broad potential in both settings, providing a treatment for multiple indications with high unmet medical needs.
